Coave Therapeutics
Agnès Gouble has a diverse work experience across various companies and roles. Starting in 1997, they worked as an intern at Pierre Fabre. Agnès then pursued a PhD at Centre de Biologie du Développement CNRS from 1997 to 2001. Following that, they worked as a post-doctoral researcher at CIML in 2001-2002. Agnès joined Cellectis in 2002 as a Project Leader in the R&D department, focusing on genome engineering tools. Agnès became an R&D team manager at Cellectis Therapeutics in 2007 and continued in various roles within Cellectis until 2012, including Preclinical Director and Scientific Alliance Manager. In 2018, they were promoted to SVP Preclinical at Cellectis. Most recently, in 2022, Agnès joined Coave Therapeutics as the VP Program Management. Agnès has expertise in molecular biology, cellular biology, in vivo proof of concept, scientific program management, and establishment of scientific partnerships.
Agnès Gouble completed their Master of Engineering (M.Eng.) in Biotechnology from INSA Toulouse, France, from 1994 to 1997. Agnès then pursued a PhD in Molecular and Cellular Biology from the University of Toulouse, France. No specific start and end dates were provided for their PhD.
This person is not in any offices
Coave Therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.